NCT05998642 is a Phase 2 clinical trial of Methotrexate in Non-hodgkin Lymphoma, sponsored by Canadian Cancer Trials Group.

Who is sponsoring NCT05998642?

NCT05998642 is sponsored by Canadian Cancer Trials Group.

What drugs are being tested in NCT05998642?

Interventions in NCT05998642: Methotrexate, Rituximab (where available), Ibrutinib.

What condition does NCT05998642 study?

NCT05998642 studies Non-hodgkin Lymphoma.

Is NCT05998642 still recruiting?

NCT05998642 is currently recruiting now. Last updated 14 April 2026.

Last reviewed 2026-04-14 · How we verify

NCT05998642

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Recruiting now Phase 2 Last updated 14 April 2026

What this trial tests

Phase 2 trial testing Methotrexate in Non-hodgkin Lymphoma in 30 participants. Currently enrolling.

Timeline

13 February 2024

Primary endpoint
31 May 2028

31 December 2028

Quick facts

Lead sponsor	Canadian Cancer Trials Group
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	13 February 2024
Primary completion	31 May 2028
Estimated completion	31 December 2028
Sites	8 locations across Canada

Drugs / interventions tested

Methotrexate — full drug profile →
Rituximab (where available) — full drug profile →
Ibrutinib (ibrutinib) — full drug profile →

Conditions studied

Non-hodgkin Lymphoma — all drugs for Non-hodgkin Lymphoma →

Sponsor

Canadian Cancer Trials Group — full company profile →

Who can join

18 and older, any sex, with Non-hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as the care most people get for Primary Central Nervous System Lymphoma (PCNSL).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Orelabrutinib plus reduced-dose whole brain radiotherapy in elderly primary central nervous system lymphoma: a case report.
Wang Q, Wang H, Tang D, Wu Y, et al · · 2025 · PMID 41256329 · DOI 10.3389/fonc.2025.1693481

Verify or expand the search:

Other trials of Methotrexate

Trials testing the same drug.

NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07477691 — Immune Modulation During Palynziq® Treatment in Adults (IMPALA) · Phase 4 · not yet recruiting

Other recruiting trials for Non-hodgkin Lymphoma

Currently open trials in the same condition.

NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06299462 — PTCy and ATG for MSD and MUD Transplants · Phase 1, PHASE2 · recruiting
NCT06393335 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory C · EARLY_PHASE1 · recruiting
NCT06323525 — TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting

Other Canadian Cancer Trials Group trials

Trials by the same sponsor.

NCT07390435 — Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials · not yet recruiting
NCT07297667 — GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · Phase 1 · not yet recruiting
NCT06630273 — Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherape · not yet recruiting
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05998642 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Canadian Cancer Trials Group
Last refreshed: 14 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05998642.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing